NCT04627753View on ClinicalTrials.gov

Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

November 2, 2025

Study Completion Date

November 2, 2026

Conditions
Primary CNS Lymphoma
Interventions
DRUG

Rituximab, lenalidomide

Maintenance for 2 years

Trial Locations (1)

135710

RECRUITING

Samsung Medical Center, Seoul

Sponsors

Collaborators (1)

Celltrion
All Listed Sponsors
collaborator

Celltrion

INDUSTRY

collaborator

Samyang Biopharmaceuticals Corporation

INDUSTRY

lead

Kim, Seok Jin

OTHER

NCT04627753 - Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. | Biotech Hunter | Biotech Hunter